Gateway Investment Advisers LLC grew its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 1.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 51,174 shares of the company’s stock after acquiring an additional 975 shares during the period. Gateway Investment Advisers LLC’s holdings in Ionis Pharmaceuticals were worth $1,933,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. CWM LLC grew its holdings in shares of Ionis Pharmaceuticals by 14.2% during the 3rd quarter. CWM LLC now owns 1,963 shares of the company’s stock worth $87,000 after acquiring an additional 244 shares during the period. Captrust Financial Advisors grew its stake in shares of Ionis Pharmaceuticals by 21.1% in the 2nd quarter. Captrust Financial Advisors now owns 1,429 shares of the company’s stock worth $53,000 after buying an additional 249 shares during the last quarter. Delphia USA Inc. grew its stake in shares of Ionis Pharmaceuticals by 3.1% in the 3rd quarter. Delphia USA Inc. now owns 9,597 shares of the company’s stock worth $424,000 after buying an additional 286 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Ionis Pharmaceuticals by 7.1% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,708 shares of the company’s stock worth $208,000 after buying an additional 314 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Ionis Pharmaceuticals by 8.7% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,083 shares of the company’s stock worth $225,000 after buying an additional 487 shares during the last quarter. Hedge funds and other institutional investors own 87.32% of the company’s stock.
Ionis Pharmaceuticals Price Performance
NASDAQ IONS opened at $33.62 on Friday. The business’s fifty day moving average price is $37.77 and its 200-day moving average price is $40.73. The stock has a market capitalization of $4.81 billion, a price-to-earnings ratio of -17.69 and a beta of 0.57. The company has a debt-to-equity ratio of 2.06, a current ratio of 7.07 and a quick ratio of 7.00. Ionis Pharmaceuticals, Inc. has a 1-year low of $31.46 and a 1-year high of $48.82.
Analyst Ratings Changes
Several analysts recently weighed in on IONS shares. SVB Securities cut their price target on Ionis Pharmaceuticals from $34.00 to $27.00 in a research note on Thursday, February 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $65.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, February 23rd. Morgan Stanley cut Ionis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $56.00 to $40.00 in a research report on Wednesday, December 21st. SVB Leerink lowered their price objective on Ionis Pharmaceuticals from $34.00 to $27.00 and set a “market perform” rating on the stock in a research report on Thursday, February 23rd. Finally, Piper Sandler upped their price objective on Ionis Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Thursday, January 19th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $45.17.
Insider Activity
In other news, EVP Eric Swayze sold 1,815 shares of the stock in a transaction on Monday, February 6th. The stock was sold at an average price of $40.79, for a total transaction of $74,033.85. Following the transaction, the executive vice president now directly owns 31,941 shares of the company’s stock, valued at approximately $1,302,873.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Joseph Klein III sold 2,000 shares of the company’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $40.00, for a total value of $80,000.00. Following the completion of the sale, the director now directly owns 16,791 shares in the company, valued at approximately $671,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric Swayze sold 1,815 shares of the company’s stock in a transaction on Monday, February 6th. The stock was sold at an average price of $40.79, for a total value of $74,033.85. Following the completion of the sale, the executive vice president now owns 31,941 shares of the company’s stock, valued at $1,302,873.39. The disclosure for this sale can be found here. Insiders have sold 74,022 shares of company stock valued at $2,961,208 in the last ninety days. 2.36% of the stock is currently owned by company insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T.
Featured Stories
- Get a free copy of the StockNews.com research report on Ionis Pharmaceuticals (IONS)
- KB Home Strong Results Lift Prices
- Chewy Stock Is Setting Up For Long-Term Profitable Growth
- Why Wall Street Loves These 3 Penny Stocks
- Low Volume Bunge Plunge Presents an Opportunity
- Carvana May Be Able To Reach Profitability This Year
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
